Alcyomics Limited

Osteoarthritis (OA) is a painful and disabling disease of the joints. It principally affects the hands, hips and knees and is very common in most countries. It is estimated that over 250 million people have osteoarthritis which has a significant impact on global economies and healthcare systems. Osteoarthritis is the most common form of arthritis in the U...

Osteoarthritis is a painful and disabling disease of the joints. It principally affects the hands, hips and knees and is very common in most countries. It is estimated that over 250 million people across the world have osteoarthritis which has a significant impact on global economies and healthcare systems. Osteoarthritis is the most common form of arthri...

Alcyomics has developed unique non-animal non-artificial human skin explant assays (Skimune & Skimune3D) which can test for safety and efficacy of novel drugs and compounds including cosmetics. Skimune and Skimune 3D have been developed by using human skin, tissue and blood therefore giving a human response to the compounds rather than, the currently used...

Extension For Impact Funding Our results to date have shown that within the general population there are responders, mild or non responders to the COVID-19 virus. This will allow us to identify those individuals who may respond well to a vaccine and those individuals that may need further, or additional, therapy for COVID-19. The extension for impact fund...

"The Northern Alliance Advanced Therapies Treatment Centre (NAATTC) is a group of NHS hospitals and services. NAATTC has a wide geographical reach across Scotland and the North of England and is responsible for the health care of 15 million NHS patients. Advanced therapies are becoming increasingly available with a growing number of companies developing t...

Alcyomics have developed unique, non-animal, non-artificial human skin explant assays (Skimune™ and Skimune™3D) which can test for safety and efficacy of novel drugs and compounds, including cosmetics. Alcyomics assays enable the products of the pharmacuetical, chemical and cosmetics industries to reach the clinic and/or the market place, quicker by early...

Awaiting Public Project Summary

Alcyomics Ltd, has developed a novel proof of concept human skin equivalent model (Skimune™-3D) from our current patented skin assay (Skimune™). Both assays use healthy volunteer blood and skin samples to assess drugs and compounds for adverse immune reactions. Our objective, using Launchpad funding is to make a reproducable manufacturable Skimune™-3D mod...

To develop a novel 3D human skin equivalent model which will allow entry into new markets for skin sensation and detection of adverse immune responses to novel compounds and drugs.

Awaiting Public Project Summary